Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma

Author:

Huang Richard S. P.,Haberberger James,Murugesan Karthikeyan,Danziger Natalie,Hiemenz Matthew,Severson Eric,Duncan Daniel L.,Ramkissoon Shakti H.,Ross Jeffrey S.ORCID,Elvin Julia A.,Lin Douglas I.ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Reference30 articles.

1. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1–17.

2. American Cancer Society. Key statistics for cervical cancer; 2020.

3. Board PDQATE. Cervical cancer treatment (PDQ®): patient version. In: PDQ cancer information summaries. National Cancer Institute (US), Bethesda (MD); 2002.

4. FDA. FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy; 2018.

5. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470–8.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3